Distalmotion announced that it received CE Mark approval for its Dexter surgical robot for minimally invasive surgical care.
Lausanne, Switzerland-based Distalmotion said in a news release that its Dexter system combines the affordability of laparoscopy with the benefits of robotic surgery to increase simplicity and versatility in the space.
Distalmotion said Dexter is ready for clinical use following the approval, which came after successful validation of Dexter from surgeons and nurses across European hospitals.
“Obtaining European CE Mark is a major milestone paving the ground for the clinical use of Dexter in Europe,” Distalmotion CEO Michael Friedrich said in the release. “Dexter has already garnered tremendous interest in the surgical community and we look forward to answering the increasing demand for a medical device removing the complexity out of robotic surgery to fast track its widespread adoption in minimally invasive surgical care.
“Following the validation of our product clinical value and benefits earlier this year, I am now looking forward to starting a broader movement allowing every patient to access the benefits of robotic surgery”
